3 Reasons to Sell AMPL and 1 Stock to Buy Instead
Since October 2024, Amplitude has been in a holding pattern, posting a small loss of 0.6% while floating around $8.96.
3 Reasons MDU is Risky and 1 Stock to Buy Instead
MDU Resources has gotten torched over the last six months - since October 2024, its stock price has dropped 42.8% to $16.95 per share. This was partly driven by its softer quarterly results and might have investors contemplating their next move.
3 Reasons to Sell JAZZ and 1 Stock to Buy Instead
Jazz Pharmaceuticals currently trades at $109.85 per share and has shown little upside over the past six months, posting a small loss of 1.4%.
3 Reasons to Avoid DNOW and 1 Stock to Buy Instead
Since April 2020, the S&P 500 has delivered a total return of 92.4%. But one standout stock has nearly doubled the market - over the past five years, DistributionNOW has surged 162% to $15.52 per share. Its momentum hasn’t stopped as it’s also gained 29.5% in the last six months thanks to its solid quarterly results, beating the S&P by 34.9%.
Winners And Losers Of Q1: Churchill Downs (NASDAQ:CHDN) Vs The Rest Of The Consumer Discretionary Stocks
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the consumer discretionary industry, including Churchill Downs (NASDAQ:CHDN) and its peers.
Generic Pharmaceuticals Stocks Q4 Teardown: Viatris (NASDAQ:VTRS) Vs The Rest
Let’s dig into the relative performance of Viatris (NASDAQ:VTRS) and its peers as we unravel the now-completed Q4 generic pharmaceuticals earnings season.
3 Reasons to Sell MKC and 1 Stock to Buy Instead
McCormick trades at $74.11 per share and has stayed right on track with the overall market, losing 5.4% over the last six months while the S&P 500 is down 5.4%. This was partly driven by its softer quarterly results and might have investors contemplating their next move.
3 Reasons GIII is Risky and 1 Stock to Buy Instead
Although the S&P 500 is down 5.4% over the past six months, G-III’s stock price has fallen further to $25.58, losing shareholders 18.3% of their capital. This may have investors wondering how to approach the situation.
A Look Back at Engineering and Design Services Stocks’ Q4 Earnings: EMCOR (NYSE:EME) Vs The Rest Of The Pack
Let’s dig into the relative performance of EMCOR (NYSE:EME) and its peers as we unravel the now-completed Q4 engineering and design services earnings season.
3 Reasons to Avoid AMRC and 1 Stock to Buy Instead
Shareholders of Ameresco would probably like to forget the past six months even happened. The stock dropped 66.9% and now trades at $10.51. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation.